Form D · Pharmaceuticals
Daisy Pharma Opioid Venture, LLC
Scottsdale, AZ · CIK 0001729659
Offering snapshot reported Feb 6, 2018 · SEC filing
- Reported sold
- Yet to sell Offering amount: $75M
- Investors reported
- 0 Form D · investor count
- Minimum accepted
- $1M Reported outside-investor minimum
- First sale
- Yet to occur As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 6, 2018 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06c
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $4M (estimated)
- Finders' fees
- $0
- Form D file number
- 021-304949
Source: Form D, filed Feb 6, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Brent Berj Nerguizian | Executive |
| Kendric Burton Speagle | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
23623 N. Scottsdale Rd., #D3269
Scottsdale, AZ, 85255
Scottsdale, AZ, 85255